kaliumchlorid/glucose 0,3 % + 5 % b. braun
b.braun melsungen ag, nemecko - elektrolyty so sacharidmi - 76 - infundibilia
kaliumchlorid/glucose 0,15 % + 5 % b. braun
b.braun melsungen ag, nemecko - elektrolyty so sacharidmi - 76 - infundibilia
chlorid sodný 0,9 % imuna envibag
imuna pharm, a.s., slovensko - elektrolyty - 76 - infundibilia
glucose 20 % w/v intravenous infusion b.p. bieffe
bieffe medital s.p.a., taliansko - sacharidy - 76 - infundibilia
glucose 10 % w/v intravenous infusion b.p. bieffe
bieffe medital s.p.a., taliansko - sacharidy - 76 - infundibilia
bupropion neuraxpharm 150 mg tablety s riadeným uvoľňovaním
neuraxpharm bohemia s.r.o., Česká republika - bupropión - 30 - antidepressiva
bupropion neuraxpharm 300 mg tablety s riadeným uvoľňovaním
neuraxpharm bohemia s.r.o., Česká republika - bupropión - 30 - antidepressiva
pemazyre
incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastické činidlá - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastické činidlá - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
cisplatin kabi 1 mg/ml
fresenius kabi oncology plc. - cisplatina - 44 - cytostatica